Pharmaceutical company Endo International plc (NASDAQ:ENDP) said on Friday that it has signed a non-exclusive agreement to provide fill-finish manufacturing services at its plant in Rochester, Michigan for the NVX-CoV2373 COVID-19 vaccine candidate from Novavax Inc.
The agreement has been executed between the company's subsidiary, Par Sterile Products LLC and Novavax Inc for NVX-CoV2373.
NVX–CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS–CoV–2, the virus that causes COVID-19 disease. NVX–CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains its patented saponin-based Matrix-M adjuvant to enhance and stimulate high levels of neutralizing antibodies.
In conjunction with the agreement, Par Sterile's Rochester facility has started production of Novavax's NVX-CoV2373 final drug product, with initial batches to be used in Novavax' pivotal Phase 3 clinical trial in the US. Par Sterile will fill-finish NVX-CoV2373 vaccine intended for commercial distribution in the US.
Currently, Novavax Inc's NVX-CoV2373 is in multiple Phase 2 clinical trials to evaluate the safety and immunogenicity of NVX-CoV2373 in the US and Australia building on positive Phase 1 results and expanding to include older adults. A Phase 2b clinical trial to assess efficacy began in South Africa in August 2020. Interim data for these trials is expected before the end of 2020.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval